Essential Roles of EphB Receptors and EphrinB Ligands in Endothelial Cell Function and Angiogenesis

Advances in Cancer Research

Volumn 114, Issue , 2012, Pages 21-57

  Salvucci, Ombretta ^a   Tosato, Giovanna ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Endothelial cells; Eph; Ephrin; Signaling; Tumor; Vascular remodeling; VEGF; Vessel sprouting

Indexed keywords

AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOL PROPIONIC ACID; ANGIOPOIETIN 1; CAVEOLIN 1; CLATHRIN; EPHRIN; EPHRIN A4; EPHRIN A5; EPHRIN B2; EPHRIN RECEPTOR B1; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B3; EPHRIN RECEPTOR B4; EPHRIN RECEPTOR B5; EPHRIN RECEPTOR B6; FIBROBLAST GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; G PROTEIN COUPLED RECEPTOR KINASE INTERACTING PROTEIN; GLUTAMATE RECEPTOR; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PRESENILIN 1; PROTEIN CDC42; PROTEIN KINASE B; RAC PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ACTIN FILAMENT; ANGIOGENESIS; ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; BLOOD BRAIN BARRIER; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CORPUS LUTEUM; CYTOTROPHOBLAST; DEPHOSPHORYLATION; DIABETIC RETINOPATHY; ENDOCYTOSIS; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; FIBRIN CLOT; FIBROBLAST; GENE EXPRESSION; HEART DEVELOPMENT; HUMAN; HYPOXIA; LOSS OF FUNCTION MUTATION; MESENCHYMAL STEM CELL; MONOCYTE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NEUTROPHIL; NONHUMAN; PERICYTE; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REGULATORY MECHANISM; RETINA MACULA AGE RELATED DEGENERATION; RETROLENTAL FIBROPLASIA; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TUMOR GROWTH; WOUND HEALING; ZEBRA FISH;

EID: 84860807231     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386503-8.00002-8     Document Type: Chapter

References (177)

1. Adams R.H., Wilkinson G.A., Weiss C., Diella F., Gale N.W., Deutsch U., Risau W., Klein R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 1999, 13:295-306.
2. Adams R.H., Diella F., Hennig S., Helmbacher F., Deutsch U., Klein R. The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell 2001, 104:57-69.
3. Alon T., Hemo I., Itin A., Pe'er J., Stone J., Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1995, 1:1024-1028.
4. Armulik A., Abramsson A., Betsholtz C. Endothelial/pericyte interactions. Circ. Res. 2005, 97:512-523.
5. Armulik A., Genove G., Mae M., Nisancioglu M.H., Wallgard E., Niaudet C., He L., Norlin J., Lindblom P., Strittmatter K., Johansson B.R., Betsholtz C. Pericytes regulate the blood-brain barrier. Nature 2010, 468:557-561.
6. Augustin H.G., Koh G.Y., Thurston G., Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-tie system. Nat. Rev. Mol. Cell Biol. 2009, 10:165-177.
7. Banks R.E., Forbes M.A., Kinsey S.E., Stanley A., Ingham E., Walters C., Selby P.J. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br. J. Cancer 1998, 77:956-964.
8. Bao P., Kodra A., Tomic-Canic M., Golinko M.S., Ehrlich H.P., Brem H. The role of vascular endothelial growth factor in wound healing. J. Surg. Res. 2009, 153:347-358.
9. Batlle E., Henderson J.T., Beghtel H., van den Born M.M., Sancho E., Huls G., Meeldijk J., Robertson J., van de Wetering M., Pawson T., Clevers H. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002, 111:251-263.
10. Benedito R., Roca C., Sorensen I., Adams S., Gossler A., Fruttiger M., Adams R.H. The Notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009, 137:1124-1135.
11. Bentley K., Mariggi G., Gerhardt H., Bates P.A. Tipping the balance: robustness of tip cell selection, migration and fusion in angiogenesis. PLoS Comput. Biol. 2009, 5:e1000549.
12. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111:1287-1295.
13. Bong Y.S., Lee H.S., Carim-Todd L., Mood K., Nishanian T.G., Tessarollo L., Daar I.O. ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:17305-17310.
14. Boutros M., Mlodzik M. Dishevelled: at the crossroads of divergent intracellular signaling pathways. Mech. Dev. 1999, 83:27-37.
15. Brantley-Sieders D., Schmidt S., Parker M., Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr. Pharm. Des. 2004, 10:3431-3442.
16. Bruckner K., Pasquale E.B., Klein R. Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 1997, 275:1640-1643.
17. Castellvi J., Garcia A., de la Torre J., Hernandez J., Gil A., Xercavins J., Ramon y Cajal S. Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis. Hum. Pathol. 2006, 37:883-889.
18. Chappell J.C., Taylor S.M., Ferrara N., Bautch V.L. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev. Cell 2009, 17:377-386.
19. Chong L.D., Park E.K., Latimer E., Friesel R., Daar I.O. Fibroblast growth factor receptor-mediated rescue of x-ephrin B1-induced cell dissociation in Xenopus embryos. Mol. Cell. Biol. 2000, 20:724-734.
20. Chrencik J.E., Brooun A., Recht M.I., Kraus M.L., Koolpe M., Kolatkar A.R., Bruce R.H., Martiny-Baron G., Widmer H., Pasquale E.B., Kuhn P. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure 2006, 14:321-330.
21. Chrencik J.E., Brooun A., Recht M.I., Nicola G., Davis L.K., Abagyan R., Widmer H., Pasquale E.B., Kuhn P. Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J. Biol. Chem. 2007, 282:36505-36513.
22. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2011, 10:505-514.
23. Cortina C., Palomo-Ponce S., Iglesias M., Fernandez-Masip J.L., Vivancos A., Whissell G., Huma M., Peiro N., Gallego L., Jonkheer S., Davy A., Lloreta J., et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat. Genet. 2007, 39:1376-1383.
24. Cowan C.A., Henkemeyer M. The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature 2001, 413:174-179.
25. Cowan C.A., Yokoyama N., Saxena A., Chumley M.J., Silvany R.E., Baker L.A., Srivastava D., Henkemeyer M. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development. Dev. Biol. 2004, 271:263-271.
26. Cowan C.W., Shao Y.R., Sahin M., Shamah S.M., Lin M.Z., Greer P.L., Gao S., Griffith E.C., Brugge J.S., Greenberg M.E. Vav family GEFs link activated Ephs to endocytosis and axon guidance. Neuron 2005, 46:205-217.
27. Crisan M., Yap S., Casteilla L., Chen C.W., Corselli M., Park T.S., Andriolo G., Sun B., Zheng B., Zhang L., Norotte C., Teng P.N., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
28. Cuevas P., Gutierrez-Diaz J.A., Reimers D., Dujovny M., Diaz F.G., Ausman J.I. Pericyte endothelial gap junctions in human cerebral capillaries. Anat. Embryol. (Berl) 1984, 170:155-159.
29. Damsky C.H., Fitzgerald M.L., Fisher S.J. Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo. J. Clin. Invest. 1992, 89:210-222.
30. Davalos V., Dopeso H., Castano J., Wilson A.J., Vilardell F., Romero-Gimenez J., Espin E., Armengol M., Capella G., Mariadason J.M., Aaltonen L.A., Schwartz S., et al. EPHB4 and survival of colorectal cancer patients. Cancer Res. 2006, 66:8943-8948.
31. Dayan F., Mazure N.M., Brahimi-Horn M.C., Pouyssegur J. A dialogue between the hypoxia-inducible factor and the tumor microenvironment. Cancer Microenviron. 2008, 1:53-68.
32. Deroanne C., Vouret-Craviari V., Wang B., Pouyssegur J. EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway. J. Cell Sci. 2003, 116:1367-1376.
33. Dohn M., Jiang J., Chen X. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 2001, 20:6503-6515.
34. Dopeso H., Mateo-Lozano S., Mazzolini R., Rodrigues P., Lagares-Tena L., Ceron J., Romero J., Esteves M., Landolfi S., Hernandez-Losa J., Castano J., Wilson A.J., et al. The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res. 2009, 69:7430-7438.
35. Dravis C., Henkemeyer M. Ephrin-B reverse signaling controls septation events at the embryonic midline through separate tyrosine phosphorylation-independent signaling avenues. Dev. Biol. 2011, 355:138-151.
36. Dumont D.J., Gradwohl G., Fong G.H., Puri M.C., Gertsenstein M., Auerbach A., Breitman M.L. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 1994, 8:1897-1909.
37. Egawa M., Yoshioka S., Higuchi T., Sato Y., Tatsumi K., Fujiwara H., Fujii S. Ephrin B1 is expressed on human luteinizing granulosa cells in corpora lutea of the early luteal phase: the possible involvement of the B class Eph-ephrin system during corpus luteum formation. J. Clin. Endocrinol. Metab. 2003, 88:4384-4392.
38. Egea J., Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol. 2007, 17:230-238.
39. Erber R., Eichelsbacher U., Powajbo V., Korn T., Djonov V., Lin J., Hammes H.P., Grobholz R., Ullrich A., Vajkoczy P. EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J. 2006, 25:628-641.
40. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
41. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
42. Fisher S.J., Cui T.Y., Zhang L., Hartman L., Grahl K., Zhang G.Y., Tarpey J., Damsky C.H. Adhesive and degradative properties of human placental cytotrophoblast cells in vitro. J. Cell Biol. 1989, 109:891-902.
43. Foo S.S., Turner C.J., Adams S., Compagni A., Aubyn D., Kogata N., Lindblom P., Shani M., Zicha D., Adams R.H. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell 2006, 124:161-173.
44. Fraisl P., Mazzone M., Schmidt T., Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev. Cell 2009, 16:167-179.
45. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., Worthen G.S., Albelda S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: " N1" versus " N2" TAN. Cancer Cell 2009, 16:183-194.
46. Fukai J., Yokote H., Yamanaka R., Arao T., Nishio K., Itakura T. EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. Mol. Cancer Ther. 2008, 7:2768-2778.
47. Fuller T., Korff T., Kilian A., Dandekar G., Augustin H.G. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J. Cell Sci. 2003, 116:2461-2470.
48. Gale N.W., Baluk P., Pan L., Kwan M., Holash J., DeChiara T.M., McDonald D.M., Yancopoulos G.D. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev. Biol. 2001, 230:151-160.
49. Gariano R.F., Gardner T.W. Retinal angiogenesis in development and disease. Nature 2005, 438:960-966.
50. Georgakopoulos A., Litterst C., Ghersi E., Baki L., Xu C., Serban G., Robakis N.K. Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. EMBO J. 2006, 25:1242-1252.
51. Gerety S.S., Anderson D.J. Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 2002, 129:1397-1410.
52. Gerety S.S., Wang H.U., Chen Z.F., Anderson D.J. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol. Cell 1999, 4:403-414.
53. Gerhardt H., Golding M., Fruttiger M., Ruhrberg C., Lundkvist A., Abramsson A., Jeltsch M., Mitchell C., Alitalo K., Shima D., Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 2003, 161:1163-1177.
54. Hellstrom M., Gerhardt H., Kalen M., Li X., Eriksson U., Wolburg H., Betsholtz C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 2001, 153:543-553.
55. Hellstrom M., Phng L.K., Hofmann J.J., Wallgard E., Coultas L., Lindblom P., Alva J., Nilsson A.K., Karlsson L., Gaiano N., Yoon K., Rossant J., et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445:776-780.
56. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Molecular plasticity of human melanoma cells. Oncogene 2003, 22:3070-3075.
57. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 2003, 3:411-421.
58. Herbert S.P., Huisken J., Kim T.N., Feldman M.E., Houseman B.T., Wang R.A., Shokat K.M., Stainier D.Y. Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science 2009, 326:294-298.
59. Himanen J.P., Nikolov D.B. Eph signaling: a structural view. Trends Neurosci. 2003, 26:46-51.
60. Himanen J.P., Rajashankar K.R., Lackmann M., Cowan C.A., Henkemeyer M., Nikolov D.B. Crystal structure of an Eph receptor-ephrin complex. Nature 2001, 414:933-938.
61. Holland S.J., Gale N.W., Gish G.D., Roth R.A., Songyang Z., Cantley L.C., Henkemeyer M., Yancopoulos G.D., Pawson T. Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J. 1997, 16:3877-3888.
62. Huang F., Reeves K., Han X., Fairchild C., Platero S., Wong T.W., Lee F., Shaw P., Clark E. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007, 67:2226-2238.
63. Hunkapiller N.M., Gasperowicz M., Kapidzic M., Plaks V., Maltepe E., Kitajewski J., Cross J.C., Fisher S.J. A role for Notch signaling in trophoblast endovascular invasion and in the pathogenesis of pre-eclampsia. Development 2011, 138:2987-2998.
64. Huynh-Do U., Vindis C., Liu H., Cerretti D.P., McGrew J.T., Enriquez M., Chen J., Daniel T.O. Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. J. Cell Sci. 2002, 115:3073-3081.
65. Irie F., Okuno M., Pasquale E.B., Yamaguchi Y. EphrinB-EphB signalling regulates clathrin-mediated endocytosis through tyrosine phosphorylation of synaptojanin 1. Nat. Cell Biol. 2005, 7:501-509.
66. Jager R.D., Mieler W.F., Miller J.W. Age-related macular degeneration. N. Engl. J. Med. 2008, 358:2606-2617.
67. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
68. Jin Y.J., Wang J., Qiao C., Hei T.K., Brandt-Rauf P.W., Yin Y. A novel mechanism for p53 to regulate its target gene ECK in signaling apoptosis. Mol. Cancer Res. 2006, 4:769-778.
69. Kalo M.S., Pasquale E.B. Signal transfer by Eph receptors. Cell Tissue Res. 1999, 298:1-9.
70. Kemp H.A., Cooke J.E., Moens C.B. EphA4 and EfnB2a maintain rhombomere coherence by independently regulating intercalation of progenitor cells in the zebrafish neural keel. Dev. Biol. 2009, 327:313-326.
71. Kertesz N., Krasnoperov V., Reddy R., Leshanski L., Kumar S.R., Zozulya S., Gill P.S. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 2006, 107:2330-2338.
72. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
73. Kim I., Ryu Y.S., Kwak H.J., Ahn S.Y., Oh J.L., Yancopoulos G.D., Gale N.W., Koh G.Y. EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J. 2002, 16:1126-1128.
74. Klein R. Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat. Neurosci. 2009, 12:15-20.
75. Knoll B., Drescher U. Src family kinases are involved in EphA receptor-mediated retinal axon guidance. J. Neurosci. 2004, 24:6248-6257.
76. Koolpe M., Burgess R., Dail M., Pasquale E.B. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J. Biol. Chem. 2005, 280:17301-17311.
77. Korff T., Braun J., Pfaff D., Augustin H.G., Hecker M. Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment. Blood 2008, 112:73-81.
78. Krasnoperov V., Kumar S.R., Ley E., Li X., Scehnet J., Liu R., Zozulya S., Gill P.S. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am. J. Pathol. 2010, 176:2029-2038.
79. Kullander K., Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell Biol. 2002, 3:475-486.
80. Kumar S.R., Masood R., Spannuth W.A., Singh J., Scehnet J., Kleiber G., Jennings N., Deavers M., Krasnoperov V., Dubeau L., Weaver F.A., Sood A.K., et al. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br. J. Cancer 2007, 96:1083-1091.
81. Kumar S.R., Scehnet J.S., Ley E.J., Singh J., Krasnoperov V., Liu R., Manchanda P.K., Ladner R.D., Hawes D., Weaver F.A., Beart R.W., Singh G., et al. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res. 2009, 69:3736-3745.
82. Kvanta A., Algvere P.V., Berglin L., Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 1996, 37:1929-1934.
83. Lampugnani M.G., Orsenigo F., Gagliani M.C., Tacchetti C., Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 2006, 174:593-604.
84. Lanahan A.A., Hermans K., Claes F., Kerley-Hamilton J.S., Zhuang Z.W., Giordano F.J., Carmeliet P., Simons M. VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev. Cell 2010, 18:713-724.
85. Lauterbach J., Klein R. Release of full-length EphB2 receptors from hippocampal neurons to cocultured glial cells. J. Neurosci. 2006, 26:11575-11581.
86. Lee H.S., Bong Y.S., Moore K.B., Soria K., Moody S.A., Daar I.O. Dishevelled mediates ephrinB1 signalling in the eye field through the planar cell polarity pathway. Nat. Cell Biol. 2006, 8:55-63.
87. Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., Ferrara N., Nagy A., Roos K.P., Iruela-Arispe M.L. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130:691-703.
88. Lee H.S., Mood K., Battu G., Ji Y.J., Singh A., Daar I.O. Fibroblast growth factor receptor-induced phosphorylation of ephrinB1 modulates its interaction with Dishevelled. Mol. Biol. Cell 2009, 20:124-133.
89. Li J.L., Sainson R.C., Oon C.E., Turley H., Leek R., Sheldon H., Bridges E., Shi W., Snell C., Bowden E.T., Wu H., Chowdhury P.S., et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011, 71:6073-6083.
90. Librach C.L., Werb Z., Fitzgerald M.L., Chiu K., Corwin N.M., Esteves R.A., Grobelny D., Galardy R., Damsky C.H., Fisher S.J. 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. J. Cell Biol. 1991, 113:437-449.
91. Lin D., Gish G.D., Songyang Z., Pawson T. The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif. J. Biol. Chem. 1999, 274:3726-3733.
92. Liu Y., Wada R., Yamashita T., Mi Y., Deng C.X., Hobson J.P., Rosenfeldt H.M., Nava V.E., Chae S.S., Lee M.J., Liu C.H., Hla T., et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 2000, 106:951-961.
93. Lobov I.B., Renard R.A., Papadopoulos N., Gale N.W., Thurston G., Yancopoulos G.D., Wiegand S.J. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:3219-3224.
94. Lopez P.F., Sippy B.D., Lambert H.M., Thach A.B., Hinton D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 1996, 37:855-868.
95. Lu Q., Sun E.E., Klein R.S., Flanagan J.G. Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoattraction. Cell 2001, 105:69-79.
96. Maekawa H., Oike Y., Kanda S., Ito Y., Yamada Y., Kurihara H., Nagai R., Suda T. Ephrin-B2 induces migration of endothelial cells through the phosphatidylinositol-3 kinase pathway and promotes angiogenesis in adult vasculature. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2008-2014.
97. Makinen T., Adams R.H., Bailey J., Lu Q., Ziemiecki A., Alitalo K., Klein R., Wilkinson G.A. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev. 2005, 19:397-410.
98. Mann F., Miranda E., Weinl C., Harmer E., Holt C.E. B-type Eph receptors and ephrins induce growth cone collapse through distinct intracellular pathways. J. Neurobiol. 2003, 57:323-336.
99. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
100. Mao W., Luis E., Ross S., Silva J., Tan C., Crowley C., Chui C., Franz G., Senter P., Koeppen H., Polakis P. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 2004, 64:781-788.
101. Margolis S.S., Salogiannis J., Lipton D.M., Mandel-Brehm C., Wills Z.P., Mardinly A.R., Hu L., Greer P.L., Bikoff J.B., Ho H.Y., Soskis M.J., Sahin M., et al. EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell 2010, 143:442-455.
102. Marston D.J., Dickinson S., Nobes C.D. Rac-dependent trans-endocytosis of ephrinBs regulates Eph-ephrin contact repulsion. Nat. Cell Biol. 2003, 5:879-888.
103. Masood R., Xia G., Smith D.L., Scalia P., Still J.G., Tulpule A., Gill P.S. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood 2005, 105:1310-1318.
104. Meyer S., Hafner C., Guba M., Flegel S., Geissler E.K., Becker B., Koehl G.E., Orso E., Landthaler M., Vogt T. Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int. J. Oncol. 2005, 27:1197-1206.
105. Miao H., Strebhardt K., Pasquale E.B., Shen T.L., Guan J.L., Wang B. Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J. Biol. Chem. 2005, 280:923-932.
106. Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J., Basilion J.P., Sedor J., Wu J., Danielpour D., Sloan A.E., Cohen M.L., et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009, 16:9-20.
107. Miller J.W., Adamis A.P., Shima D.T., D'Amore P.A., Moulton R.S., O'Reilly M.S., Folkman J., Dvorak H.F., Brown L.F., Berse B., et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 1994, 145:574-584.
108. Mohle R., Green D., Moore M.A., Nachman R.L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:663-668.
109. Murai K.K., Pasquale E.B. 'Eph'ective signaling: forward, reverse and crosstalk. J. Cell Sci. 2003, 116:2823-2832.
110. Murai K.K., Pasquale E.B. New exchanges in eph-dependent growth cone dynamics. Neuron 2005, 46:161-163.
111. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
112. Murohara T., Horowitz J.R., Silver M., Tsurumi Y., Chen D., Sullivan A., Isner J.M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998, 97:99-107.
113. Nishimura T., Yamaguchi T., Kato K., Yoshizawa M., Nabeshima Y., Ohno S., Hoshino M., Kaibuchi K. PAR-6-PAR-3 mediates Cdc42-induced Rac activation through the Rac GEFs STEF/Tiam1. Nat. Cell Biol. 2005, 7:270-277.
114. Noguera-Troise I., Daly C., Papadopoulos N.J., Coetzee S., Boland P., Gale N.W., Lin H.C., Yancopoulos G.D., Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444:1032-1037.
115. Noren N.K., Pasquale E.B. Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell. Signal. 2004, 16:655-666.
116. Noren N.K., Pasquale E.B. Paradoxes of the EphB4 receptor in cancer. Cancer Res. 2007, 67:3994-3997.
117. Noren N.K., Foos G., Hauser C.A., Pasquale E.B. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat. Cell Biol. 2006, 8:815-825.
118. Ogita H., Kunimoto S., Kamioka Y., Sawa H., Masuda M., Mochizuki N. EphA4-mediated Rho activation via Vsm-RhoGEF expressed specifically in vascular smooth muscle cells. Circ. Res. 2003, 93:23-31.
119. Palmer A., Zimmer M., Erdmann K.S., Eulenburg V., Porthin A., Heumann R., Deutsch U., Klein R. EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol. Cell 2002, 9:725-737.
120. Pasquale E.B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 2010, 10:165-180.
121. Pitulescu M.E., Adams R.H. Eph/ephrin molecules-a hub for signaling and endocytosis. Genes Dev. 2010, 24:2480-2492.
122. Pugh C.W., Ratcliffe P.J. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin. Cancer Biol. 2003, 13:83-89.
123. Red-Horse K., Kapidzic M., Zhou Y., Feng K.T., Singh H., Fisher S.J. EPHB4 regulates chemokine-evoked trophoblast responses: a mechanism for incorporating the human placenta into the maternal circulation. Development 2005, 132:4097-4106.
124. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., Maira G., Parati E.A., Stassi G., Larocca L.M., De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
125. Ridgway J., Zhang G., Wu Y., Stawicki S., Liang W.C., Chanthery Y., Kowalski J., Watts R.J., Callahan C., Kasman I., Singh M., Chien M., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
126. Ruhe J.E., Streit S., Hart S., Wong C.H., Specht K., Knyazev P., Knyazeva T., Tay L.S., Loo H.L., Foo P., Wong W., Pok S., et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res. 2007, 67:11368-11376.
127. Ruhrberg C., Gerhardt H., Golding M., Watson R., Ioannidou S., Fujisawa H., Betsholtz C., Shima D.T. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 2002, 16:2684-2698.
128. Sahin M., Greer P.L., Lin M.Z., Poucher H., Eberhart J., Schmidt S., Wright T.M., Shamah S.M., O'Connell S., Cowan C.W., Hu L., Goldberg J.L., et al. Eph-dependent tyrosine phosphorylation of ephexin1 modulates growth cone collapse. Neuron 2005, 46:191-204.
129. Salvucci O., de la Luz Sierra M., Martina J.A., McCormick P.J., Tosato G. EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood 2006, 108:2914-2922.
130. Salvucci O., Maric D., Economopoulou M., Sakakibara S., Merlin S., Follenzi A., Tosato G. EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 2009, 114:1707-1716.
131. Sato T.N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995, 376:70-74.
132. Sawamiphak S., Ritter M., Acker-Palmer A. Preparation of retinal explant cultures to study ex vivo tip endothelial cell responses. Nat. Protoc. 2010, 5:1659-1665.
133. Sawamiphak S., Seidel S., Essmann C.L., Wilkinson G.A., Pitulescu M.E., Acker T., Acker-Palmer A. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010, 465:487-491.
134. Scehnet J.S., Ley E.J., Krasnoperov V., Liu R., Manchanda P.K., Sjoberg E., Kostecke A.P., Gupta S., Kumar S.R., Gill P.S. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 2009, 113:254-263.
135. Schruefer R., Sulyok S., Schymeinsky J., Peters T., Scharffetter-Kochanek K., Walzog B. The proangiogenic capacity of polymorphonuclear neutrophils delineated by microarray technique and by measurement of neovascularization in wounded skin of CD18-deficient mice. J. Vasc. Res. 2006, 43:1-11.
136. Schultz G.S., Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 2009, 17:153-162.
137. Segura I., Essmann C.L., Weinges S., Acker-Palmer A. Grb4 and GIT1 transduce ephrinB reverse signals modulating spine morphogenesis and synapse formation. Nat. Neurosci. 2007, 10:301-310.
138. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
139. Semenza G.L. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb. Symp. Quant. Biol 2011, Jul 22. [Epub ahead of print].
140. Shamah S.M., Lin M.Z., Goldberg J.L., Estrach S., Sahin M., Hu L., Bazalakova M., Neve R.L., Corfas G., Debant A., Greenberg M.E. EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell 2001, 105:233-244.
141. Shin D., Garcia-Cardena G., Hayashi S., Gerety S., Asahara T., Stavrakis G., Isner J., Folkman J., Gimbrone M.A., Anderson D.J. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev. Biol. 2001, 230:139-150.
142. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
143. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y.G., Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6742-6747.
144. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 1994, 35:101-111.
145. Smith F.M., Vearing C., Lackmann M., Treutlein H., Himanen J., Chen K., Saul A., Nikolov D., Boyd A.W. Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen. J. Biol. Chem. 2004, 279:9522-9531.
146. Stein E., Schoecklmann H., Daniel T.O. Eph family receptors and ligands in vascular cell targeting and assembly. Trends Cardiovasc. Med. 1997, 7:329-334.
147. Steinle J.J., Meininger C.J., Forough R., Wu G., Wu M.H., Granger H.J. Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J. Biol. Chem. 2002, 277:43830-43835.
148. Steinle J.J., Meininger C.J., Chowdhury U., Wu G., Granger H.J. Role of ephrin B2 in human retinal endothelial cell proliferation and migration. Cell. Signal. 2003, 15:1011-1017.
149. Stenzel D., Lundkvist A., Sauvaget D., Busse M., Graupera M., van der Flier A., Wijelath E.S., Murray J., Sobel M., Costell M., Takahashi S., Fassler R., et al. Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis. Development 2011, 138:4451-4463.
150. Suchting S., Freitas C., le Noble F., Benedito R., Breant C., Duarte A., Eichmann A. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:3225-3230.
151. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., Sato T.N., Yancopoulos G.D. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
152. Suri C., McClain J., Thurston G., McDonald D.M., Zhou H., Oldmixon E.H., Sato T.N., Yancopoulos G.D. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998, 282:468-471.
153. Tanaka M., Kamo T., Ota S., Sugimura H. Association of Dishevelled with Eph tyrosine kinase receptor and ephrin mediates cell repulsion. EMBO J. 2003, 22:847-858.
154. Tanaka M., Ohashi R., Nakamura R., Shinmura K., Kamo T., Sakai R., Sugimura H. Tiam1 mediates neurite outgrowth induced by ephrin-B1 and EphA2. EMBO J. 2004, 23:1075-1088.
155. Tang M., Chen B., Lin T., Li Z., Pardo C., Pampo C., Chen J., Lien C.L., Wu L., Ai L., Wang H., Yao K., et al. Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:15231-15236.
156. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., McDonald D.M. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999, 286:2511-2514.
157. Toth J., Cutforth T., Gelinas A.D., Bethoney K.A., Bard J., Harrison C.J. Crystal structure of an ephrin ectodomain. Dev. Cell 2001, 1:83-92.
158. Vihanto M.M., Vindis C., Djonov V., Cerretti D.P., Huynh-Do U. Caveolin-1 is required for signaling and membrane targeting of EphB1 receptor tyrosine kinase. J. Cell Sci. 2006, 119:2299-2309.
159. Wang H.U., Chen Z.F., Anderson D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998, 93:741-753.
160. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K.E., Geber A., Fligelman B., Leversha M., Brennan C., Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
161. Wang Y., Nakayama M., Pitulescu M.E., Schmidt T.S., Bochenek M.L., Sakakibara A., Adams S., Davy A., Deutsch U., Luthi U., Barberis A., Benjamin L.E., et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465:483-486.
162. Wybenga-Groot L.E., Baskin B., Ong S.H., Tong J., Pawson T., Sicheri F. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 2001, 106:745-757.
163. Xia G., Kumar S.R., Masood R., Zhu S., Reddy R., Krasnoperov V., Quinn D.I., Henshall S.M., Sutherland R.L., Pinski J.K., Daneshmand S., Buscarini M., et al. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005, 65:4623-4632.
164. Xia G., Kumar S.R., Stein J.P., Singh J., Krasnoperov V., Zhu S., Hassanieh L., Smith D.L., Buscarini M., Broek D., Quinn D.I., Weaver F.A., et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 2006, 25:769-780.
165. Xu N.J., Henkemeyer M. Ephrin-B3 reverse signaling through Grb4 and cytoskeletal regulators mediates axon pruning. Nat. Neurosci. 2009, 12:268-276.
166. Xu Y., Zagoura D., Keck C., Pietrowski D. Expression of Eph receptor tyrosine kinases and their ligands in human Granulosa lutein cells and human umbilical vein endothelial cells. Exp. Clin. Endocrinol. Diabetes 2006, 114:590-595.
167. Xu Z., Jin H., Qian Q. Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases. Expert Opin. Ther. Pat. 2009, 19:1035-1037.
168. Yang N.Y., Pasquale E.B., Owen L.B., Ethell I.M. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization. J. Biol. Chem. 2006, 281:32574-32586.
169. Yu J., Zhang L., Hwang P.M., Rago C., Kinzler K.W., Vogelstein B. Identification and classification of p53-regulated genes. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:14517-14522.
170. Yuan K., Jin Y.T., Lin M.T. Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis. J. Periodontal Res. 2000, 35:165-171.
171. Yuan K., Hong T.M., Chen J.J., Tsai W.H., Lin M.T. Syndecan-1 up-regulated by ephrinB2/EphB4 plays dual roles in inflammatory angiogenesis. Blood 2004, 104:1025-1033.
172. Zhong T.P., Childs S., Leu J.P., Fishman M.C. Gridlock signalling pathway fashions the first embryonic artery. Nature 2001, 414:216-220.
173. Zhou Y., Fisher S.J., Janatpour M., Genbacev O., Dejana E., Wheelock M., Damsky C.H. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?. J. Clin. Invest. 1997, 99:2139-2151.
174. Zhou Y., Bellingard V., Feng K.T., McMaster M., Fisher S.J. Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PlGF, and VEGF-C. Dev. Biol. 2003, 263:114-125.
175. Zhuang G., Brantley-Sieders D.M., Vaught D., Yu J., Xie L., Wells S., Jackson D., Muraoka-Cook R., Arteaga C., Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 2010, 70:299-308.
176. Zimmer M., Palmer A., Kohler J., Klein R. EphB-ephrinB bi-directional endocytosis terminates adhesion allowing contact mediated repulsion. Nat. Cell Biol. 2003, 5:869-878.
177. Zisch A.H., Pazzagli C., Freeman A.L., Schneller M., Hadman M., Smith J.W., Ruoslahti E., Pasquale E.B. Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses. Oncogene 2000, 19:177-187.